anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
th leading cause of cancer mortality worldwide, with an estimated 841,000 (9.3 cases per 100,000 person-years) and 782,000 deaths (8.5 deaths per 100,000 person-years) in 2018.(Bray F et al., 2018) In Egypt, it represents the fourth common cancer and the leading cause of mortality- and morbidity-related cancer .(Akinyemiju T, et al.T 2017) Many hospital based studies reported increasing the incidence of HCC The reason for increased incidence could be attributed to improvement in screening programs and diagnostic tools, increasing the survival rate of cirrhotic patients that increases the chance of developing HCC . (Ibrahim AS, et al 2014) Because the early stage disease is usually asymptomatic, approximate half of patients are diagnosed at an advanced stage. Many biomarkers, such as α-fetoprotein (AFP) have already been used to screen for HCC and choose the best treatment on an individual status. However, these biomarkers are not sufficient to predict prognosis accurately. (Kabbach G, 2015) Ferritin, as a soluble iron-storage protein, participates in iron metabolism and accumulation, which directly damage DNA and proteins by generating reactive species and cause apoptosis through activation of the caspase cascade and hyperoxidation of fatty chains(Miyanishi K et al., 2019). Additionally, it is believed to be responsible for enhanced production of collagen and liver fibrosis . (Wang W et al., 2010) Elevated serum ferritin is frequently observed among patients with liver injury, regardless of etiology. (Wong K, Adams PC, 2006) However, whether ferritin is associated with incident liver cancer remains unclear. On one hand, previous clinical and epidemiologic studies show that serum ferritin may be correlated with liver cancer risk. For example, a recent meta-analysis including nine studies showed that higher serum ferritin was associated with 1.5-fold increases in risk of liver cancer. (Tran KT et al., 2019) On the other hand, the serum ferritin levels were associated with liver cancer among HCV+ men but not women in a Japanese cohort study. (Uchino K et al 2016 ) Moreover, no study has evaluated association between serum ferritin levels and the severity of hepatic decompensation in cirrhotic patients. Therefore, we will carry out a case-control study in Al Rajhy Liver Hospital, Assiut University, to examine the association between serum ferritin concentration and the incidence of HCC and severity of hepatic impairment in subjects with liver cirrhosis.
People with HIV (PWH) have a higher age-adjusted mortality due to chronic immune activation and age-related comorbidities. PWH also have higher rates of clonal hematopoiesis (CH) than age-matched non-HIV cohorts; however, risk factors influencing the development and expansion of CH in PWH remain incompletely explored. We investigated the relationship between CH, immune biomarkers, and HIV-associated risk factors (CD4+ and CD8+ T cells, nadir CD4+ count, opportunistic infections [OIs], and immune reconstitution inflammatory syndrome [IRIS]) in a diverse cohort of 197 PWH with median age of 42 years, using a 56-gene panel. Seventy-nine percent had a CD4+ nadir below 200 cells/μL, 58.9% had prior OIs, and 34.5% had a history of IRIS. The prevalence of CH was high (27.4%), even in younger individuals, and CD8+ T cells and nadir CD4+ counts strongly associated with CH after controlling for age. A history of IRIS was associated with CH in a subgroup analysis of patients 35 years of age and older. Inflammatory biomarkers were higher in CH carriers compared with noncarriers, supporting a dysregulated immune state. These findings suggest PWH with low nadir CD4+ and/or inflammatory complications may be at high risk of CH regardless of age and represent a high-risk group that could benefit from risk reduction and potentially targeted immunomodulation.
The invention discloses a preparation method of anticancer drug nanoparticles, and relates to the field of anticancer drugs. The invention aims to solve the technical problems of poor targeting property, poor curative effect and invisible treatment of the existing anticancer drugs in clinical application. The method comprises the following steps: firstly, preparing end-capped nanoparticles; secondly, adding acetic anhydride and an acid-binding agent after dispersion, and reacting; dispersing, adding N, N-carbonyl diimidazole, and heating and refluxing; and cooling, adding the anticancer drug with hydroxyl, stirring and reacting under the condition of water bath, centrifuging, washing and drying. The medicine-carrying nano-particles prepared by the invention can be passively targeted to tumor parts by enhancing the penetration and retention effects, and the medicine and the zinc oxide nano-particles can generate a synergistic anticancer effect, so that the anticancer curative effect is improved. In addition, the zinc oxide nanoparticles can emit blue fluorescence, so that anticancer treatment is visualized. The nanoparticles prepared by the invention are used in the field of cancer treatment.
FIELD: medicine. ^ SUBSTANCE: invention refers to biotechnology. The pharmaceutical composition for destruction of tumor cells expressing the receptor CCR7 is described, which contains an antibody binding to the receptor CCR7, and a pharmaceutically acceptable carrier. Versions of methods of eradication of tumor cells expressing the receptor CCR7 are proposed, which include either contacting of the specified cells with an antibody that binds with the specified receptor CCR7, or administering to the patient a therapeutically effective amount of an antibody that binds with the specified receptor CCR7. ^ EFFECT: invention expands the amount of means for cancer treatment. ^ 6 cl, 8 dwg, 1 ex
While the intravenous formulation of cidofovir has been approved for the treatment of CMV retinitis in HIV-infected individuals, information is limited regarding its safety and tolerance in HIV-infected children. Intravenous cidofovir requires less frequent administration for both induction and maintenance therapy of CMV retinitis than other currently available therapies. If found to be safe and well tolerated in HIV-infected children with CMV retinitis, intravenous cidofovir would add significantly to agents available to treat this debilitating opportunistic infection.

In this two-part study, patients are stratified by age (3 months to \< 2 years versus 2 years to \< 13 years). In Part A, 8 patients (4 per cohort) receive a single intravenous dose of cidofovir with concurrent probenecid. If 1 patient in a cohort experiences life-threatening grade 3/4 toxicity, accrual for that cohort is stopped. If 1 patient in a cohort experiences non-life-threatening grade 3/4 toxicity, 2 additional patients are entered in that cohort. A second dose of cidofovir may be studied in Part A based on the pharmacokinetic and safety data obtained with the initial dose. Patients who complete Part A of the study without serious toxicity may be treated in Part B.

In Part B, 12 patients (8 in the older cohort and 4 in the younger cohort) receive maintenance therapy with cidofovir at the dose established in Part A. Patients who complete 6 months of treatment in Part B may continue therapy until all patients have completed the study. NOTE: For patients who require induction or reinduction, cidofovir is given weekly for 2 weeks before initiating the Part B regimen.

\[AS PER AMENDMENT 1/7/98: Each subject receives sequential single doses of intravenous cidofovir, with a 2-week interval between doses and with concurrent probenecid. If the single doses prove safe and well tolerated and individual pharmacokinetic profiles are acceptable, subjects proceed to multi-dosing cidofovir given every 2 weeks for 6 months beginning 14-21 days after the second single dose. Subjects remain on intravenous or oral ganciclovir for treatment of CMV retinitis until they enter the multi-dosing phase of the study. Subjects who require reinduction during the multi-dosing phase receive intravenous cidofovir once weekly for 2 weeks before resuming the every-2-weeks regimen. Patients are stratified by age (3 months to \< 2 years vs. 2 years to \< 13 years), with 4 patients entered in the younger cohort and 8 in the older. In the younger age cohort, if 1 patient experiences life- or vision-threatening grade 3/4 toxicity or 2 experience non-life-threatening grade 3/4 toxicity, the age cohort will stop. If 1 patient experiences non-life-threatening grade 3/4 toxicity, 2 additional patients will be enrolled in this age cohort. In the older age cohort, if 1 patient experiences severe life- or vision-threatening toxicity or 2 experience serious, non-life-threatening toxicities, enrollment for both cohorts will be suspended while safety data are reviewed. If 2 of the 8 patients experience severe, non-life-threatening toxicity, enrollment may continue.\]
To supply the  ginkgo biloba  extract which contains no ginkgolic acid but the active ingredient of existing  ginkgo biloba  extract and which achieves significant effects in activation of the brain cells. The composition comprises nanoparticle  ginkgo biloba  extract as the active ingredient, which has the effect of brain function activation. The  ginkgo biloba  extract is free of ginkgolic acid and is made with the breakdown method, the combination of dry and wet process, crushing  ginkgo biloba  extract powder. The nanoparticle is 100 nm and below. The above composition has the form from the group consisting of condiments, food additives, food materials, food and drink, health food and drink, drugs, quasi drugs and feeding stuffs. The above health food and drink is for patients with abnormality in cerebral blood flow and metabolism and with the effect of brain function activation prevents or improves the symptom. The above drugs and quasi drugs are intended for human or animal use.
The LIFT study will document the first clinical use of the ZiftLift Tissue Anchor in a browlift for patients with age-related brow ptosis. It is a single arm, open label multicenter study, to evaluate the safety and efficacy of the Zift Lift System. Up to 20 subjects in up to 3 sites will be enrolled in this study. Data from this trial will be used to confirm the device safety and efficacy and provide inputs to further refine the device design and procedure technique for future device iterations Subjects with signed informed consents and who meet all the inclusion and none of the exclusion criteria and are treated with the device will be considered enrolled in the study. An interim report will be created after the first 20 patients has completed their 90 follow up and the data monitored. The 20 patients, 90 day report may be submitted to FDA and other agencies for product clearance and registrations. After FDA clearance has been obtained, the study may be converted to a post-market study for the long term follow up.
A system for the transdermal delivery of drugs, vitamins, or micronutrients over a time interval of up to one month. The transdermal delivery system employs a plurality of varying diameter bioactive glass capsules configured to react with water in the bloodstream to break down and release a contained dose of a drug, vitamin, or other micronutrients. The bioactive glass capsules are microscopic and able to be absorbed through the skin. An adhesive bandage is adhered to the skin via an adhesive layer. A concealed membrane is positioned centrally on an inner surface of the adhesive bandage and separated by a barrier layer. The bioactive glass capsules are housed within the concealed membrane until the patch is placed on the skin allowing them to absorb through the skin to deliver up to a month's dose of the drug, vitamin, or other micronutrients into the bloodstream.
The invention relates to the technical field of sanitary articles and provides a traditional Chinese medicine health-care protective pad and a preparation method thereof. The protective pad is anti-bacterial, can relieve itching and remove peculiar smells, is safe and free of side effects, and has the functions of promoting blood circulation to remove blood stasis, clearing away heat and toxic materials, calming the nerves, regulating internal secretion and enhancing immunity and defense capacity of females, and accordingly gynecological diseases are effectively prevented and treated. The protective pad comprises a hydrophilic anti-bacterial gauze layer, a traditional Chinese medicine core layer and a waterproof bottom layer. The traditional Chinese medicine core layer is formed by a traditional Chinese medicine compound wrapped in high-polymer moisture-absorbing non-woven cloth. The traditional Chinese medicine compound is prepared from, by weight, 15-25 parts of borneol, 21-30 parts of sophora flavescens, 18-28 parts of chitin, 15-25 parts of tuber fleeceflower stems, 20-30 parts of a sterilizing itching-relieving compound and 0-5 parts of sap high-water-absorption resin. The sterilizing itching-relieving compound is prepared from, by weight, 25-34 parts of chlorpheniramine maleate, 25-34 parts of cinnarizine and 38-45 parts of sky fruit powder.
OBJECTIVE: Limited research has directly compared the effectiveness of aqua- and land-based exercises for postexercise recovery. This study aimed to fill this gap by comparing the effects of these 2 types of exercises on postexercise recovery.
METHODS: Sixteen male college athletes participated in an 8-day experimental study. The initial 2 days were dedicated to determining the intensity levels for the muscle-damaging exercise and recovery jogging. In a crossover design, participants underwent 2 sets of experimental trials. They were randomly assigned to either an aqua or land recovery intervention for days 3 to 5, and after a 1-week washout period they switched to the opposite intervention for days 6 to 8. Muscle soreness, creatine kinase, anaerobic performance, countermovement-jump height, and flexibility were assessed at different time points: baseline, immediately after downhill running, within 1 hour after jogging, and 24 hours and 48 hours after aqua or land jogging.
RESULTS: Significant group × time interaction effects were detected in the perceived soreness of the hamstring and quadriceps. However, the post hoc analysis showed no significant difference between aqua and land jogging groups. No significant group × time interaction effect was observed in creatine kinase, anaerobic performance, countermovement-jump height, or flexibility.
CONCLUSION: Aqua and land jogging have similar recovery effects on muscle soreness and performance-based parameters.
PURPOSE:To increase the production of interferon-alpha (abbreviated as IFN-alpha) and to enable the mass production of IFN-alpha, by containing an IFN-alpha-producing cell with a lower alcohol, and inducing the cell. CONSTITUTION:An IFN-alpha-producing cell (e.g. cultured lymphoblastoid cell such as Namalva strain) is cultured in a medium to produce IFN-alpha. In the above process, the IFN-alpha-producing cell is made to contact with a lower alcohol (e.g. ethanol) prior to the induction. The contact is carried out preferably in a medium having the ultimate concentration of the lower alcohol of 0.1-3(V/V)%. The production of IFN-alpha can be increased, and a large amount of IFN-alpha can be produced by this process.
The invention relates to a new cationic antimicrobial peptide and application thereof, belonging to the technical field of biochemical polypeptide medicines. The new cationic antimicrobial peptide is a small molecule polypeptide which is designed artificially and synthesized chemically by taking a natural antimicrobial peptide in skin secretions of rana temporaria chensinensis david as a template. The small molecule polypeptide comprises 13 amino acid residues, and the C terminal of the small molecule polypeptide is amidated. The small molecule polypeptide has the sequence of IKKILSKIKKLLK-NH2, the molecular weight of 1552.13Da and the isoelectric point of 10.70, and the small molecule polypeptide has 6 positive charges. Tests prove that the small molecule polypeptide has broad-spectrum inhibiting and killing effects on a variety of bacteria and human cancer cells in vitro and has no hemolytic activity and eukaryotic cell toxicity in an antimicrobial and anticancer concentration range, and drug resistance is not easy to produce. In addition, experiments on animals show that the small molecule polypeptide has the effect of resisting wound infection. The small molecule polypeptide has small molecular weight, is synthesized artificially and conveniently, has extremely high application value and can be used for preparing new antibacterial, anti-inflammatory and anti-cancer medicines.
More advanced imaging methods are needed to reliably distinguish benign small renal masses (SRM) from renal cell carcinoma (RCC) to prevent invasive biopsies or unnecessary surgery. Similarly, improved imaging methods are needed for unambiguous detection of lesions suspect for metastatic and relapse RCC during follow-up. Girentuximab is an antibody against Carbonic Anhydrase IX (CAIX), an antigen that is expressed on the cell surface of 95% of clear cell RCC (ccRCC). Zr-89-girentuximab PET/CT may be a valuable imaging technique in the diagnosis of patients with RCC. The aim of the present study is to show the impact of the Zr-89-girentuximab PET/CT on the clinical management of ccRCC patients. Thirty patients will be included in whom conventional diagnostics are inconclusive. During a multidisciplinary team (MDT) the hypothetical next step in the clinical process will be noted (e.g. further diagnostics, treatment or active surveillance). Subsequently, in these patients a Zirconium-89-girentuximab PET/CT will be performed. Patients will receive a single intravenous dose of 5 mg Zirconium-89-girentuximab (37 MBq). A PET/CT scan will be acquired 4 or 5 days after injection. The Zirconium-89-girentuximab PET/CT will be read by a clinician with extensive experience in radiolabeled girentuximab imaging. The results of the PET/CT will be discussed during the MDT and will be used to decide what the next step in the clinical process will be. This step will be compared with the hypothetical next step from the MDT before the scan.
Silodosin capsules is the brand name for silodosin, a selective antagonist of alpha-1 adrenoreceptors. The chemical name of silodosin is 1-(3- Hydroxypropyl)-5-[(2R)-2-({2-[2-(2,2,2-trifluoroethoxy) phenoxy]ethyl} amino) propyl]-2,3-dihydro-1H-indole-7-carboxamide and the molecular formula is C 25H 32F 3N 3O 4 with a molecular weight of 495.53. The structural formula of silodosin is: 

Silodosin is a white to pale yellowish white powder that melts at approximately 104.72 to 107.5 °C. It is freely soluble in acetic acid, and in absolute alcohol, and insoluble in water.   
  
Each Silodosin 8 mg capsule for oral administration contains 8 mg silodosin, and the following inactive ingredients: magnesium stearate, magnesium aluminometasilicate, mannitol, polysorbate 80 and pregelatinized starch. The size #1 hard gelatin capsules contain gelatin and titanium dioxide. The capsules are printed with edible ink containing shellac, propylene glycol, black iron oxide and potassium hydroxide.   
  
Each Silodosin 4 mg capsule for oral administration contains 4 mg silodosin, and the following inactive ingredients: magnesium stearate, magnesium aluminometasilicate, mannitol, polysorbate 80 and pregelatinized starch. The size #3 hard gelatin capsules contain gelatin and titanium dioxide. The capsules are printed with edible ink containing shellac, propylene glycol, black iron oxide and potassium hydroxide.
Patients who tested for HIV and consent to participate in the study watch a a 15-minute HIV posttest educational video available in English/Spanish. Afterwards, patients complete an assessment tool concerning HIV prevention and transmission.
Design A prospective, placebo-controlled trial. H\&N cancer patients eligible for curative treatment will be randomised to receive standard nutritional support with placebo (15ml/day Sunflower oil, control group) or nutritional support with omega-3 FA supplementation (15ml/day Echium oil, experimental group) during radio(chemo)therapy. All patients will undergo a nutritional screening (Patient-Generated Subjective Global Assessment), a quality of life evaluation (EORTC QLQ C30 \& HN35) and will be asked to keep a 3-day food diary at the start of their therapy, and again during the 4th week and the end of therapy. Body composition and grip strength will be measured with bio-electrical impedance (BIA) analysis, Dual X-ray absorptiometry (DXA) and the JAMAR® hydraulic hand dynamometer once at baseline, and again in the 4th week of therapy. Blood samples are collected at baseline, and in the 4th week of therapy to (1) verify compliance rate by measuring fatty acid concentration, (2) verify the presence of potential biomarkers that can predict cachexia and (3) to detect the presence of SNPs associated with severe acute dysphagia. Demographic data, tumour characteristics and therapy-related toxicity will also be collected.

Population Newly diagnosed non-metastatic (stage I-IVB) head and neck cancer patients (≥18 or older) eligible for curative primary or adjuvant radiotherapy with or without systemic therapy
In collaboration with the Department of Radiation Oncology and the Interventional Radiology Service, patients with lung or liver cancer or lung or liver metastases in whom FDG PET/CT is part of the clinical standard of care for disease evaluation and response assessment will be enrolled in this study. We will perform a clinical PET/CT and BH PET/CT (for two bed positions covering the entire chest) prior to, and again 1-2 weeks after SBRT or RFA. This early time point is chosen because a few weeks after the completion of treatment, acute radiation injury in the lung begins and will likely be detectable as abnormal uptake on follow-up PET imaging making it difficult to assess tumor recurrence.
We examined the role of phonemic awareness [PA], rapid naming [RAN], and verbal short-term memory [VSTM], phonological verbal fluency (PVF) along with literacy related skills (letter naming and orthographic knowledge) in reading, spelling, and numeracy performances. The study was carried out on a sample that consists of 245 native Arabic children of grade 1 and 2. The results showed a significant effect of Group on PA, RAN, VSTM, PVF, and letter naming and orthographic knowledge. There is also a comorbidity effect on PA and orthographic knowledge. The regression analysis indicated that PA and orthographic knowledge are the strongest predictors of the three academic outcomes, whereas VSTM, PVF and RAN displayed less predictive relationships with reading, spelling and numeracy. The results suggest that there are a number of underpinning factors that are linked to PA and orthographic knowledge, which are also accounted for a comorbidity condition between literacy and numeracy.
The invention relates to the technical field of medicine, and specifically relates to nitrogen-substituted dihydroartemisinin phenyl ether, optical isomers thereof and a preparation method thereof; pharmaceutical compositions with the derivatives as active components; and applications thereof in preparing medicines used for treating and/or preventing various cancers. The compound or pharmaceutically acceptable salts thereof have a structure as the following. The variables are as described in the claims and in the specifications. According to the invention, a pair of epimers with dihydroartemisinin C-10 site of R or S configuration can be prepared at a same time and with an equal amount, and separation can be realized. The prepared compounds have a significant effect in inhibiting cancer cell growth, and a selective killing effect against drug-resistant cells. The compounds have a potential of overcoming multidrug resistance.